Philippe Pouletty Elected President of France Biotech, the French Biotech Industry Association; Succeeds Pascal Brandys

Plans to Promote Growth of French Biotech Industry on National

And International Stage



Apr 26, 2001, 01:00 ET from France Biotech

    PARIS, April 26 /PRNewswire/ -- France Biotech, the French biotechnology
 industry association (www.france-biotech.org), today announced the election of
 Philippe Pouletty, MD, as its new president.  Dr. Pouletty is also the
 chairman of DrugAbuse Sciences, a biotechnology company located in France and
 California.  He succeeds Pascal Brandys, who was a founder of France Biotech
 in 1997, but opted not to seek an additional term.  Mr. Brandys will continue
 with the association as president emeritus.  France Biotech also announced its
 new board of directors.
     "France offers tremendous research and development capabilities in life
 sciences," said Philippe Pouletty, the association's newly elected president.
 He added:  "biotechnology improves the quality of life and public health, and
 the emerging biotechnology industry should now expand faster in France.  It
 has the potential to be the leader in Europe."
     Dr. Pouletty notes that U.S. biotechnology companies are bringing as many
 new drugs to market as large pharmaceutical companies, not yet the case in
 Europe.  To that end, France Biotech will propose new legislation to the
 French government to facilitate technology transfer, attract entrepreneurs,
 European and foreign investors, and position biotechnology as a leading
 industry.  France Biotech will also play a significant role in helping young
 companies and research laboratories network and grow on an international
 basis.
     "I wish to thank Pascal Brandys for his remarkable leadership and the
 board of directors for building France Biotech into such a strong organization
 in France and Europe," Dr Pouletty added.
     "We are very pleased that Philippe has accepted the presidency of France
 Biotech," said Pascal Brandys.  "His research and entrepreneurial background
 as well as his international experience set an example for the French biotech
 industry.  Now a powerful industry representative, France Biotech will help
 the French biotechnology industry mature and expand rapidly."
     The elected members of the Board of Directors of France Biotech are:
 
     Alain Guedon -- ABTECH
     Philippe Pouletty -- DRUGABUSE SCIENCES
     Jean-Francois Mouney -- GENFIT
     Jean-Louis Escary -- GENODYSSEE
     Jean-Loup Salzmann -- GENOPOETIC
     A. Donny Strosberg -- HYBRIGENICS
     Jean-Loup Romet-Lemonne -- IDM
     Claude Hennion -- MOLECULAR ENGINES LABORATORIES
     P.Henri Schmelck -- PRIME BIOTECH
     Michel Kaczorek -- SYNT:EM
     Antoine Beret -- TROPHOS
     Henri Biscarrat -- ARTHUR ANDERSEN
     Francois Deneux -- ARTHUR D. LITTLE
     Philippe Cramer -- COMPAGNIE FINANCIERE E. DE ROTSCHILD
     Denis Lucquin -- SOFINNOVA PARTNERS
     Florence Lazard -- ERNEST GUTMANN YVES PLASSEREAUD
     Pascal Brandys, Honorary President and board member of GENSET.
 
     Philippe Pouletty, 42, MD is an immunologist and graduate of
 Pasteur Institute in Paris.  He was a Stanford University researcher and
 founder of several biotechnology companies in North America and France,
 including DrugAbuse Sciences, ConjuChem and SangStat.  DrugAbuse Sciences, a
 privately held company headquartered in California with a wholly owned
 subsidiary in Paris, is a leader in the development of novel therapies to
 treat alcoholism and drug addiction.  ConjuChem is a Montreal-based public
 company developing long-acting therapeutic compounds.  SangStat is a
 U.S.-based public company leader in the field of organ and bone marrow
 transplantation.
     Pascal Brandys is a co-founder of Genset, a French and U.S.-based genomics
 public company committed to generating a pipeline of drug candidates for the
 treatment of central nervous system and metabolic disorders.
 
     About France Biotech
     Founded in 1997, France Biotech currently has 82 members representing most
 French biotechnology companies.  The non-profit association is the industry
 representative and interacts with the government, the pharmaceutical industry,
 research institutes, the media and financial communities.  France Biotech has
 helped develop new legislation to better enable scientists start and join
 private companies, and attract larger resources to venture capital funds.
 France Biotech objectives include:
 
     -- Educating policy makers, the media and the general public on the
        scientific, medical and economic impact of biotechnology;
     -- Surveying the French and international biotechnology industry and
        providing prospective financial and economic data;
     -- Obtaining new legislation from French and European governments to
        accelerate the growth of the biotechnology industry, and assisting in
        the definition of new regulations in France and Europe;
     -- Promoting networking of French research laboratories and biotechnology
        companies on an international basis.
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X25254244
 
 

SOURCE France Biotech
    PARIS, April 26 /PRNewswire/ -- France Biotech, the French biotechnology
 industry association (www.france-biotech.org), today announced the election of
 Philippe Pouletty, MD, as its new president.  Dr. Pouletty is also the
 chairman of DrugAbuse Sciences, a biotechnology company located in France and
 California.  He succeeds Pascal Brandys, who was a founder of France Biotech
 in 1997, but opted not to seek an additional term.  Mr. Brandys will continue
 with the association as president emeritus.  France Biotech also announced its
 new board of directors.
     "France offers tremendous research and development capabilities in life
 sciences," said Philippe Pouletty, the association's newly elected president.
 He added:  "biotechnology improves the quality of life and public health, and
 the emerging biotechnology industry should now expand faster in France.  It
 has the potential to be the leader in Europe."
     Dr. Pouletty notes that U.S. biotechnology companies are bringing as many
 new drugs to market as large pharmaceutical companies, not yet the case in
 Europe.  To that end, France Biotech will propose new legislation to the
 French government to facilitate technology transfer, attract entrepreneurs,
 European and foreign investors, and position biotechnology as a leading
 industry.  France Biotech will also play a significant role in helping young
 companies and research laboratories network and grow on an international
 basis.
     "I wish to thank Pascal Brandys for his remarkable leadership and the
 board of directors for building France Biotech into such a strong organization
 in France and Europe," Dr Pouletty added.
     "We are very pleased that Philippe has accepted the presidency of France
 Biotech," said Pascal Brandys.  "His research and entrepreneurial background
 as well as his international experience set an example for the French biotech
 industry.  Now a powerful industry representative, France Biotech will help
 the French biotechnology industry mature and expand rapidly."
     The elected members of the Board of Directors of France Biotech are:
 
     Alain Guedon -- ABTECH
     Philippe Pouletty -- DRUGABUSE SCIENCES
     Jean-Francois Mouney -- GENFIT
     Jean-Louis Escary -- GENODYSSEE
     Jean-Loup Salzmann -- GENOPOETIC
     A. Donny Strosberg -- HYBRIGENICS
     Jean-Loup Romet-Lemonne -- IDM
     Claude Hennion -- MOLECULAR ENGINES LABORATORIES
     P.Henri Schmelck -- PRIME BIOTECH
     Michel Kaczorek -- SYNT:EM
     Antoine Beret -- TROPHOS
     Henri Biscarrat -- ARTHUR ANDERSEN
     Francois Deneux -- ARTHUR D. LITTLE
     Philippe Cramer -- COMPAGNIE FINANCIERE E. DE ROTSCHILD
     Denis Lucquin -- SOFINNOVA PARTNERS
     Florence Lazard -- ERNEST GUTMANN YVES PLASSEREAUD
     Pascal Brandys, Honorary President and board member of GENSET.
 
     Philippe Pouletty, 42, MD is an immunologist and graduate of
 Pasteur Institute in Paris.  He was a Stanford University researcher and
 founder of several biotechnology companies in North America and France,
 including DrugAbuse Sciences, ConjuChem and SangStat.  DrugAbuse Sciences, a
 privately held company headquartered in California with a wholly owned
 subsidiary in Paris, is a leader in the development of novel therapies to
 treat alcoholism and drug addiction.  ConjuChem is a Montreal-based public
 company developing long-acting therapeutic compounds.  SangStat is a
 U.S.-based public company leader in the field of organ and bone marrow
 transplantation.
     Pascal Brandys is a co-founder of Genset, a French and U.S.-based genomics
 public company committed to generating a pipeline of drug candidates for the
 treatment of central nervous system and metabolic disorders.
 
     About France Biotech
     Founded in 1997, France Biotech currently has 82 members representing most
 French biotechnology companies.  The non-profit association is the industry
 representative and interacts with the government, the pharmaceutical industry,
 research institutes, the media and financial communities.  France Biotech has
 helped develop new legislation to better enable scientists start and join
 private companies, and attract larger resources to venture capital funds.
 France Biotech objectives include:
 
     -- Educating policy makers, the media and the general public on the
        scientific, medical and economic impact of biotechnology;
     -- Surveying the French and international biotechnology industry and
        providing prospective financial and economic data;
     -- Obtaining new legislation from French and European governments to
        accelerate the growth of the biotechnology industry, and assisting in
        the definition of new regulations in France and Europe;
     -- Promoting networking of French research laboratories and biotechnology
        companies on an international basis.
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X25254244
 
 SOURCE  France Biotech